LRX Command Center

Network revenue is $42.6M YTD, up 9.4% vs prior year driven by Memorial Hermann and Ascension specialty volume growth. Oncology contributes 41% of total revenue. Action: replicate Memorial Hermann formulary strategy across remaining sites to capture an additional $3.2M.

Total scripts at 18,420 this period, an 8.1% increase MoM. Growth is concentrated in immunology (+14%) and oncology (+11%) classes. New biosimilar launches added 340 incremental scripts. Monitor: staffing at University of Michigan Health may bottleneck further growth.

Network-wide PDC adherence is 87.3%, 2.7 pts below the 90% target. The gap is concentrated in newly enrolled patients during their first 90 days. SMS adherence PDSA at Memorial Hermann showed a 4.2 pt improvement. Recommendation: roll out SMS program to all sites.

Memorial Hermann leads at $12.4M (29% of network revenue), followed by Ascension at $9.8M. Onvida trails at $6.1M, partially due to low capture rate. Closing the capture gap at Onvida alone would add an estimated $2.8M annually. Action: prioritize Onvida referral workflow improvements.

Oncology commands 38% of script volume, followed by Immunology at 27%. Rare Disease is the fastest-growing class at +22% QoQ despite low volume. Two new rare disease launches in Q2 could shift the mix meaningfully. Action: secure inventory commitments for anticipated rare disease demand.